Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT01383447 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

NIH

Sponsor class

Stopped This study was halted prematurely by the NCI for low accrual.

Conditions

Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia

Interventions

DRUG: entinostat
DRUG: imatinib mesylate
OTHER: laboratory biomarker analysis
OTHER: pharmacological study
GENETIC: western blotting
OTHER: immunohistochemistry staining method
OTHER: flow cytometry
GENETIC: polymerase chain reaction
OTHER: high performance liquid chromatography
OTHER: mass spectrometry

Sponsor

National Cancer Institute (NCI)